ADAMO, BARBARA
 Distribuzione geografica
Continente #
NA - Nord America 1.694
EU - Europa 1.555
AS - Asia 259
Continente sconosciuto - Info sul continente non disponibili 2
AF - Africa 1
OC - Oceania 1
SA - Sud America 1
Totale 3.513
Nazione #
US - Stati Uniti d'America 1.690
SE - Svezia 515
IE - Irlanda 443
CN - Cina 217
UA - Ucraina 148
DE - Germania 111
IT - Italia 73
FI - Finlandia 68
GB - Regno Unito 64
FR - Francia 44
PL - Polonia 35
IN - India 33
BE - Belgio 23
RU - Federazione Russa 9
AT - Austria 8
CZ - Repubblica Ceca 6
VN - Vietnam 6
CA - Canada 4
EU - Europa 2
NL - Olanda 2
PT - Portogallo 2
AU - Australia 1
CL - Cile 1
ES - Italia 1
HU - Ungheria 1
IR - Iran 1
LB - Libano 1
LV - Lettonia 1
RO - Romania 1
TR - Turchia 1
ZA - Sudafrica 1
Totale 3.513
Città #
Dublin 442
Chandler 333
Jacksonville 291
Nyköping 282
Ashburn 130
Beijing 106
Ann Arbor 85
Dearborn 81
Cambridge 64
Princeton 64
Medford 61
New York 54
Des Moines 50
Boardman 40
Warsaw 35
Lancaster 34
Pune 28
Messina 26
Brussels 23
Jinan 15
Wilmington 14
Shenyang 13
Woodbridge 13
Nanjing 11
Vienna 8
Nanchang 7
Ningbo 7
San Mateo 7
Washington 7
Dong Ket 6
Grammichele 6
Haikou 6
Hebei 6
Olomouc 6
Tianjin 6
Guangzhou 5
Hangzhou 5
Taiyuan 5
Helsinki 4
Jiaxing 4
Milan 4
Bremen 3
Catania 3
Clearwater 3
Houston 3
Lanzhou 3
Leawood 3
Reggio Calabria 3
Taizhou 3
Zhengzhou 3
Augusta 2
Brooklyn 2
Changsha 2
Fuzhou 2
Hyderabad 2
Lissone 2
London 2
Monmouth Junction 2
Montréal 2
Norwalk 2
Novokuznetsk 2
Porto 2
Acireale 1
Ardabil 1
Belfast 1
Berlin 1
Budapest 1
Cagliari 1
Cannock 1
Chapel Hill 1
Chicago 1
Delhi 1
Edinburgh 1
Filderstadt 1
Florence 1
Giugliano In Campania 1
Hendon 1
Hillsdale 1
Iasi 1
Istanbul 1
Johannesburg 1
Kemerovo 1
Lappeenranta 1
Los Angeles 1
Montreal 1
Mountain View 1
Mountmellick 1
Mumbai 1
Nanning 1
Portsmouth 1
Pozzo 1
Rockford 1
Rüsselsheim 1
Saint Petersburg 1
Serio 1
Simi Valley 1
Stephentown 1
Swansea 1
Sydney 1
Wenzhou 1
Totale 2.483
Nome #
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 91
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 86
Hereditary breast/ovarian cancer families: The impact of mutation prediction models on BRCA1/2 mutation screening costs. 79
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 77
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications. 74
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 74
Preliminary study of pre-metastatic niche (PMN) in nonmetastatic nodes for the assessment of metastasis risk in breast cancer (BC). 73
Y179C, F486L and N550H are BRCA1 variants that may be associated with breast cancer in a Sicilian family: results of a 5-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study. 72
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 71
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 67
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 65
Combination of Gemcitabine (GEM and Liposomal Pegylate Doxorubicin (PLD) in recurrent/ metastatic breast carcinoma: a phase II study. 65
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 64
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 63
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 61
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 60
Tumor Characteristics and Adjuvant treatment in Very Young Women 59
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 58
Embolia polmonare 58
Breast. La terapia primaria: stato dell'arte 58
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 57
A Missense Mutation Associated to Early Onset Breast Cancer in A Sicilian Woman. 56
BRCA1 missense variants of uncertain clinical significance in unaffected and breast/ovarian cancer of the sicilian population. 56
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 56
Phase II trial ZD1839(IRESSA)second-third line in patients with advanced/metastatic non small cell lung cancer (NSCLC):preliminary results 55
BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models. 55
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 54
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 53
A study of a new germline mutation in BRCA1 gene in two Sicilian families: a founder mutation ? 53
Q356R and S1512I are BRCA1 variants that may be associated with breast cancer in a Sicilian family. 53
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 53
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 52
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 52
Safety of Zoledronic acid in bone metastatic breast cancer patients: A retrospective analysis. 52
null 52
A rare case of malignant solitary fibrous tumor of the spinal cord 52
Neoplasie della testa collo nell’ anziano 51
BRCA1 germline mutations in sicilian breast and/or ovarian cancer families and their implications for genetic counseling. 51
Turbe della nutrizione: anoressia e cachessia. 50
Analysis of the expression levels of Leptin gene and it’s receptor in Breast Cancer patients. 50
Simultaneous development and parallel course of disseminated superficial porokeratosis and ovarian cancer: Coincidental association or true paraneoplastic syndrome? 50
Observational study to evaluate the pattern of trastuzumab (T) use and survival outcomes in HER2-positive (HER2+) early breast cancer (EBC): Regional Southern Italy experience. 49
Preclinical Development of an Intracranial Triple Negative Breast Cancer (TNBC) Tumor Model: A Pilot Study. 48
Strategia Terapeutica nel Carcinoma Prostatico Ormonorefrattario 47
Prognostic significance of elevated pretreatment serum CA-125 in patients (pts) with epithelial ovarian cancer (CEO) treated with surgery and platinum/taxane-based chemotherapy. 47
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 47
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study. 46
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 46
Infra-centimetric HER2 positive Breast Cancer: The Southern Italy Experience. 44
From Adjuvant to Preventive Breast Cancer Treatment: bridging the gap over troubled waters. 43
AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome 43
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels 42
Multicenter study in women with infracentimetric HER2 positive breast cancer: The Regional Sicilian experience. 42
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 negative lymphnodes. 42
SAFETY OF PEGILATED LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN ELDERLY WOMEN (>65 YEARS)WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER 41
Safety of trastuzumab-containing therapies in elderly women with metastatic breast cancer. 41
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 41
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 41
Stratifying triple-negative breast cancer: which definition(s) to use? 40
Phosphatidylinositol 3-kinase (PI3K) pathway activation in breast cancer brain metastases. 39
null 37
Interleukin-22 serum concentration in colon-rectal cancer patients and clinical correlations: our experience. 37
Primary Therapy in Breast Cancer: The State of the Art. 35
null 33
Risk evaluation in breast cancer: a preliminary study of pre-metastatic niche in 252 lymphnodes 29
null 22
Pre-metastatic niche identification in node negative breast cancer to assess metastasis risk. Pathological and clinical implications 19
The risk of toxicities from trastuzumab, alone or in combination, in an elderly breast cancer population. 13
Totale 3.542
Categoria #
all - tutte 11.959
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.959


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 0 1
2019/2020555 82 35 3 20 3 84 75 77 8 84 79 5
2020/2021458 68 4 95 29 21 62 12 38 8 49 41 31
2021/2022470 5 69 7 9 21 3 23 13 8 107 66 139
2022/20231.362 98 146 62 103 96 141 29 84 540 5 43 15
2023/2024342 22 49 19 33 30 136 36 1 7 3 4 2
Totale 3.542